The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
#EADV2024: Plaque psoriasis
To update you on the exciting content presented at the 2024 European Academy of Dermatology and Venereology (EADV) Congress, we have collated our social media coverage. Catch up with our live social media posts relating to plaque psoriasis below.
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Diamant Thaçi, @UniLuebeck provides an update on topical treatments for patients with psoriasis.
They highlight the safety and efficacy of topical treatments, including tapinarof and roflumilast, and discuss advancements in drug delivery… pic.twitter.com/57xLiKL1lB
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Richard Warren, @OfficialUoM examines the role of oral therapies for patients with psoriasis.
They highlight the potential benefits of oral therapies, such as cost and patient preference, and discuss the safety and efficacy of targeted… pic.twitter.com/6AKcjCXv0v
CONGRESS | #EADVCongress | PRESENTATION@Satveer_Mahil, @KingsCollegeLon, shares insights on tailoring disease prevention and treatment approaches by considering individual differences in genetics, molecular, environmental, and lifestyle factors. For patients with new onset of… pic.twitter.com/oAxLOSTNGQ
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
CONGRESS | #EADVCongress | POSTER
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 25, 2024
Matthias Augustin, @UKEHamburg presents results from an analysis of the German Psoriasis Registry PsoBest assessing the change in drug supply and choice of systemic therapies for patients with psoriasis over a 15-year period.
The proportion of… pic.twitter.com/rDGnRx0IKJ
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Ioana Cutcutache shares results from an analysis of the effects of bimekizumab treatment on the PASI sub-components at a molecular and clinical level in patients with plaque psoriasis.
Bimekizumab treatment improved all PASI sub-component… pic.twitter.com/O9GmA1iSn3
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Linfeng Li, Capital Medical University, presents post-hoc subgroup analysis results of a phase III trial (NCT04839016) evaluating the efficacy and safety of vunalizumab in 461 patients with moderate-to-severe #psoriasis, stratified by… pic.twitter.com/RIiH9U0Pn0
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Kilian Eyerich, @UniFreiburg, presents results from part 3 withdrawal phase of the phase IIIb GUIDE study investigating disease-modifying effects of guselkumab in patients with moderate-to-severe plaque #psoriasis (n=273). A total of 26… pic.twitter.com/WBk8Gp7aR3
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Khusru Asadullah, @ChariteBerlin, shares interim findings from part 3 of the phase IIIb GUIDE study assessing maintenance of response after guselkumab withdrawal in super responders (n=273). The median treatment-free period for guselkumab… pic.twitter.com/Z2MI9zAN7f
CONGRESS | #EADVCongress | PRESENTATION
— Psoriasis and Psoriatic Arthritis Hub (@psoriasis_hub) September 27, 2024
Diamant Thaçi, @UniLuebeck highlights results from the interim analysis of the observational VALUE study assessing the real-world effectiveness of risankizumab vs other biologic therapies at 2 years of treatment in adult patients with… pic.twitter.com/BOX9hdirRR
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content